Biogen to receive new board chair
Last week, it was announced that the New England Council member, Biogen, will receive its first new board chair in over nine years after a new repositioning effort.
In order to comply with the company’s age restrictions, Stelios Papadopoulos will be stepping down from her long-time position on the board. In her place, Caroline Dorsa, who has been on Biogen’s board since 2010, will oversee the board of the Cambridge drugmaker starting June 14. Dorsa’s appointment amounts to a complete changeover at the very top levels of Biogen in recent months, following Christopher Viehbacher taking over as CEO.
“The entire Board has great respect for Caroline and the tremendous contributions she has made during her 13-year tenure and as Chair of our Audit Committee, where she has exhibited exceptional judgement, integrity, and dedication,” said Dr. Papadopoulos.
The New England Council congratulates Caroline Dorsa on her new position.